New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates

Ura, Takehiro; Yamashita, Akio; Mizuki, Nobuhisa; Okuda, Kenji; Shimada, Masaru

doi:10.1016/j.vaccine.2020.11.054

Cited by 74 publications

(101 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More than 100 candidate SARS-CoV-2 vaccines are actually under development. Most of them are targeting the surface membrane S-protein that is involved in receptor binding, membrane fusion and entry into host cells [ 19 ]. Among the different vaccine platforms used so far, the mRNA-based SARS-CoV-2 vaccines have been the most attractive and the first ones to be approved by the American and European regulatory agencies (i.e., Food and Drug Administration (FDA) and European Medicines Agency (EMA)), probably owing to their rapid and low-cost manufacturing process.…”

Section: The Arrival Of Sars-cov-2 Vaccinesmentioning

confidence: 99%

“…They have been already used to obtain vaccines against other infectious diseases, such as Zika virus, influenza virus, respiratory syncytial virus (RSV), Ebola virus, and HIV [ 19 , 20 , 21 , 22 ]. On the other side, their intrinsic mRNA structure requires special attention for guaranteeing strict storage settings in order to maintain stability and translational efficiency [ 19 ]. In this context, two mRNA-based vaccines have been already licensed for commercial use after the evaluation of their respective phase III clinical trials.…”

Section: The Arrival Of Sars-cov-2 Vaccinesmentioning

confidence: 99%

“…mRNA-1273 and BNT162b2 are lipid nanoparticle-formulated nucleoside-modified RNA vaccines that encode a prefusion stabilized membrane-anchored SARS-CoV-2 full-length spike protein. They should be able to induce both humoral and cellular immunity in the base of animal studies and if phase I clinical trials [ 19 , 23 , 24 , 25 , 26 ]. The mRNA-1273 vaccine sustained a 94.1% efficacy, while a two-dose regimen of BNT162b2 showed 95% protection at preventing COVID-19 illness, including severe disease [ 2 ].…”

Section: The Arrival Of Sars-cov-2 Vaccinesmentioning

confidence: 99%

“…They are able to promote robust immune responses and can induce both humoral and cellular immunity [ 27 ]. In particular, adenovirus vectors can be easily grown to high titers in cell lines, possess elevated transduction efficiency and transgene expression, and show a broad range of viral tropism [ 19 ]. At an interim analysis of phase III trial, S protein-expressing chimpanzee adenovirus-based vaccine (ChAdOx1 nCoV-19) exhibited an acceptable safety profile and an overall efficacy of 70.4% [ 4 ].…”

Section: The Arrival Of Sars-cov-2 Vaccinesmentioning

confidence: 99%

See 3 more Smart Citations

How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists

et al. 2021

View full text Add to dashboard Cite

The severity of the COVID-19 pandemic has led to an unprecedented effort to develop vaccines against SARS-CoV-2 infection since this seems to be the most effective strategy to counter the pandemic. In the past weeks, the administration of vaccines has started in different parts of the world sustaining the hype of significantly containing the impact of SARS-CoV-2 infection. However, the rapid time lapse from vaccine development to distribution has raised several concerns on its safety and efficacy. This topic is particularly felt by patients with chronic conditions and immumodulating therapies that could compromise their immune system such as inflammatory bowel disease (IBD). Here, we explore the potential future implications of the SARS-CoV-2 vaccines introduction in the IBD field, touching upon the clinical experience coming from available data on vaccinations against other infections. We also dissect the factors associated with the acceptability of SARS-CoV-2 vaccination, describing the possible strategies that gastroenterologist should adopt to reach the highest rate of vaccinations in IBD patients.

show abstract

Section: The Arrival Of Sars-cov-2 Vaccinesmentioning

confidence: 99%

Section: The Arrival Of Sars-cov-2 Vaccinesmentioning

confidence: 99%

Section: The Arrival Of Sars-cov-2 Vaccinesmentioning

confidence: 99%

Section: The Arrival Of Sars-cov-2 Vaccinesmentioning

confidence: 99%

See 2 more Smart Citations

How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Modifications and sequence optimization of the mRNA and the particular components of the delivery vehicle can influence the immunological response. 7 Previous studies of SARS-CoV and MERS have shown that the proper choice of encoded antigen is critical 8 to avoid potential complications from antibody dependent enhancement (ADE) of disease. 9 The chemistry of the delivery vehicle is also important as the ionizable lipids that are a component of LNPs act as adjuvants but can induce adverse events 10 and the use of polyethylene glycol (PEG) in the LNP formulations can contribute to allergic reactions.…”

Section: Introductionmentioning

confidence: 99%

An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory

Haabeth¹,

Lohmeyer²,

Sallets³

et al. 2021

Preprint

View full text Add to dashboard Cite

The SARS-CoV-2 pandemic has necessitated the rapid development of prophylactic vaccines. Two mRNA vaccines have been approved for emergency use by the FDA and have demonstrated extraordinary effectiveness. The success of these mRNA vaccines establishes the speed of development and therapeutic potential of mRNA. These authorized vaccines encode full-length versions of the SARS-CoV-2 spike protein. They are formulated with Lipid Nanoparticle (LNP) delivery vehicles that have inherent immunostimulatory properties. Different vaccination strategies and alternative mRNA delivery vehicles would be desirable to ensure flexibility of future generations of SARS-CoV-2 vaccines and the development of mRNA vaccines in general. Here, we report on the development of an alternative mRNA vaccine approach using a novel delivery vehicle called Charge-Altering Releasable Transporters (CARTs). Using these inherently nonimmunogenic vehicles we are able to tailor the vaccine immunogenicity by inclusion of co-formulated adjuvants such as oligonucleotides with CpG motifs. Mice vaccinated with our mRNA-CART vaccine developed therapeutically relevant levels of RBD-specific neutralizing antibodies in both the circulation and in the lung bronchial fluids. In addition, our vaccine elicited strong and long lasting RBD-specific TH1 T cell responses including CD4+ and CD8+ T cell memory.

show abstract

Bioreactor production of rVSV‐based vectors in Vero cell suspension cultures

Kießlich

Kim

Shen

et al. 2021

Biotech & Bioengineering

View full text Add to dashboard Cite

The Vero cell line is the most used continuous cell line in viral vaccine manufacturing. This adherent cell culture platform requires the use of surfaces to support cell growth, typically roller bottles, or microcarriers. We have recently compared the production of rVSV-ZEBOV on Vero cells between microcarrier and fixed-bed bioreactors. However, suspension cultures are considered superior with regard to process scalability. Therefore, we further explore the Vero suspension system for recombinant vesicular stomatitis virus (rVSV)-vectored vaccine production. Previously, this suspension cell line was only able to be cultivated in a proprietary medium. Here, we expand the adaptation and bioreactor cultivation to a serum-free commercial medium. Following small-scale optimization and screening studies, we demonstrate bioreactor productions of highly relevant vaccines and vaccine candidates against Ebola virus disease, HIV, and coronavirus disease 2019 in the Vero suspension system. rVSV-ZEBOV, rVSV-HIV, and rVSV Ind -msp-S F -Gtc can replicate to high titers in the bioreactor, reaching 3.87 × 10 7 TCID 50 /ml, 2.12 × 10 7 TCID 50 /ml, and 3.59 × 10 9 TCID 50 /ml, respectively. Furthermore, we compare cell-specific productivities, and the quality of the produced viruses by determining the ratio of total viral particles to infectious viral particles.

show abstract

New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates

Cited by 74 publications

References 71 publications

How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists

How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists

An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory

Bioreactor production of rVSV‐based vectors in Vero cell suspension cultures

Contact Info

Product

Resources

About